EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Biofrontera's enterprise value is $13.09 Mil.
Biofrontera's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $34.07 Mil. Therefore, Biofrontera's EV-to-Revenue for today is 0.38.
The historical rank and industry rank for Biofrontera's EV-to-Revenue or its related term are showing as below:
BFRI'
s EV-to-Revenue Range Over the Past 10 Years
Min: -0.52 Med: 0.14 Max: 6.09
Current: 0.38
During the past 5 years, the highest EV-to-Revenue of Biofrontera was 6.09. The lowest was -0.52. And the median was 0.14.
BFRI's EV-to-Revenue is ranked better than 93.85% of 1025
companies
in the Drug Manufacturers industry
Industry Median: 2.36
vs BFRI: 0.38
As of today (2024-05-03), Biofrontera's stock price is $1.72.
Biofrontera's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $22.29. Therefore, Biofrontera's PS Ratio for today is 0.08.
Biofrontera EV-to-Revenue Historical Data
The historical data trend for Biofrontera's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Biofrontera's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Biofrontera's EV-to-Revenue falls into.
Biofrontera's current Enterprise Value is $13.09 Mil.
Biofrontera's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $34.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofrontera's share price for today is $1.72.
Biofrontera's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.29.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofrontera EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Biofrontera's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BFRI has been successfully added to your 